Mark Busbridge

Mark Busbridge

Auto-generated profile, based on publicly available information

Mark Busbridge

Department of Clinical Chemistry, Hammersmith Hospital, London, UK

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2009 in Kidney International
Verified
Journal Article
Closed access
PDF file
DADamien R. Ashby
Damien R. Ashby
DGDaniel P. Gale
Daniel P. Gale
MBMark Busbridge
Mark Busbridge
KMKevin Murphy
Kevin Murphy
NDNeill D. Duncan
Neill D. Duncan
PCPeter Choi
Peter Choi

1 July 2011 in JACC
Verified
Journal Article
Closed access
CRChristopher Rhodes
Christopher Rhodes
LHLuke Howard
Luke Howard
MBMark Busbridge
Mark Busbridge
DADamien Ashby
Damien Ashby
EKEumorfia Kondili
Eumorfia Kondili
MWMartin R. Wilkins
Martin R. Wilkins

14 October 2009 in Haematologica
Verified
Journal Article
Open access
PDF file
DAD. R. Ashby
D. R. Ashby
DGD. P. Gale
D. P. Gale
MBM. Busbridge
M. Busbridge
KMKevin Murphy
Kevin Murphy
NDN. D. Duncan
N. D. Duncan
PCP. Choi
P. Choi
Expression of hepcidin, the key hormone governing iron transport, is reduced by anemia in a manner which appears dependent on increased bone marrow activity. The temporal associations between plasma hepcidin and other iron parameters were examined in healthy humans after erythropoietin administration and venesection. Profound hepcidin suppression appeared abruptly 24 hours after subcutaneous erythropoietin (P=0.003), and was near maximal at onset, with peak (mid-afternoon) levels reduced by 73.2%, gradually recovering over the following two weeks. Minor changes in circulating iron, soluble transferrin receptor and growth differentiation factor-15 were observed after the reduction in hepcidin. Similar but more gradual changes in these parameters were observed after reducing hematocrit by removal of 250 mL blood. These human studies confirm the importance of a rapidly responsive marrow–hepcidin axis in regulating iron supply in vivo, and suggest that this axis is regulated by factors other than circulating iron, soluble transferrin receptor or growth differentiation factor-15.

1 December 2009 in Haematologica
Verified
Journal Article
Closed access
JKJ. J.C. Kroot
J. J.C. Kroot
EKE. H.J.M. Kemna
E. H.J.M. Kemna
SBS. S. Bansal
S. S. Bansal
MBM. Busbridge
M. Busbridge
NCN. Campostrini
N. Campostrini
DSD. W. Swinkels
D. W. Swinkels
The recently discovered iron regulatory peptide hormone hepcidin holds promise as a novel biomarker in iron metabolism disorders. To date, various mass spectrometry and immunochemical methods have been developed for its quantification in plasma and urine. Differences in methodology and analytical performance hinder the comparability of data. As a first step towards method harmonization, several hepcidin assays were compared. Worldwide eight laboratories participated in a urinary and plasma round robin in which hepcidin was analyzed. For both urine and plasma: (i) the absolute hepcidin concentrations differed widely between methods, (ii) the between-sample variation and the analytical variation of the methods are similar. Importantly, the analytical variation as percentage of the total variance is low for all methods, indicating their suitability to distinguish hepcidin levels of different samples. Spearman correlations between methods were generally high. The round robin results inform the scientific and medical community on the status and agreement of the current hepcidin methods. Ongoing initiatives should facilitate standardization by exchanging calibrators and representative samples.

1 July 2009 in Kidney International
Verified
Journal Article
Open access
PDF file
DADamien R. Ashby
Damien R. Ashby
HFHeather E. Ford
Heather E. Ford
Katie WynneKatie Wynne
Katie Wynne
AWAlison M. Wren
Alison M. Wren
KMKevin Murphy
Kevin Murphy
PCPeter Choi
Peter Choi
Malnutrition is a common complication in patients on dialysis and is strongly associated with poor prognosis. Effective therapy could substantially improve morbidity and mortality, but neither enteral nor parenteral supplementation provide long-term benefit because of the strong appetite suppression seen in such patients. We performed a double-blinded randomized crossover study of a week-long treatment with daily subcutaneous ghrelin, a gut hormone that regulates hunger through the hypothalamus, in a group of 12 malnourished dialysis patients. Ghrelin administration increased ghrelin levels in circulation, modestly reduced blood pressure for up to 2 h, and immediately and significantly increased appetite, with an increase in energy intake noted at the first study meal. Persistence of this effect throughout the week was confirmed with food diaries and final study meals. Energy expenditure, measured with free-living pulse and motion monitors, was unchanged by ghrelin. Our study shows that daily treatment with ghrelin achieves a sustained positive change in energy balance in malnourished dialysis patients. Direct manipulation of appetite with ghrelin or its analogs represents an attractive and promising therapeutic strategy for this difficult clinical problem.

5 February 2011 in Thorax
Verified
Journal Article
Open access
PDF file
ESElaine Soon
Elaine Soon
CTCarmen M Treacy
Carmen M Treacy
MTMark R Toshner
Mark R Toshner
RMRobert MacKenzie-Ross
Robert MacKenzie-Ross
VMVijay Manglam
Vijay Manglam
JPJoanna Pepke-Zaba
Joanna Pepke-Zaba
Background Anaemia is common in left heart failure and is associated with a poorer outcome. Many patients with pulmonary arterial hypertension (PAH) are anaemic or iron-deficient. This study was performed to investigate the prevalence of iron deficiency in PAH and to identify possible causes. Methods All patients with idiopathic or heritable PAH diagnosed in 1995–2008 were identified. Controls were selected from patients with chronic thromboembolic pulmonary hypertension (CTEPH). Full blood counts were examined and any abnormality was investigated. Patients were excluded if they had a cause for iron deficiency. The prevalence study was based on 85 patients with idiopathic PAH and 120 with CTEPH. A separate group of 20 patients with idiopathic PAH and 24 with CTEPH with matching haemodynamics were prospectively investigated for serum factors affecting iron metabolism. Results The prevalence study identified a point prevalence of unexplained iron deficiency of 50% in premenopausal women with idiopathic PAH compared with 8% in premenopausal women with CTEPH (p=0.002); 14% in postmenopausal women with idiopathic PAH compared with 6% in postmenopausal women with CTEPH (p=0.16); 28% in men with idiopathic PAH men compared with 2% in men with CTEPH (p=0.002); and 60% in patients with heritable PAH. The serum study showed that patients with idiopathic PAH had lower serum iron and transferrin saturations than those with CTEPH. Interleukin-6 levels correlated with iron levels(r=−0.6, p=0.006) and transferrin saturations (r=−0.68, p=0.001) in idiopathic PAH but not in CTEPH. Conclusions The prevalence of unexplained iron deficiency is significantly higher in idiopathic PAH than in CTEPH. This may be linked to interleukin-6.